Worth reading
21Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 22 August 2025Incoming appointee
1 itemScheduled Appointment Date1 October 2025
堀 英紀
Previous position（株式会社あすか製薬メディカル）取締役、あすか製薬株式会社 フェムテック事業推進室長 兼務
New position執行役員（株式会社あすか製薬メディカル 代表取締役 社長、あすか製薬株式会社 フェムテック事業推進室長 兼務）
Directors after the change9Number
Executive officers are responsible for day-to-day business execution and hold positions separate from directors under the Companies Act.
| Item | Details |
|---|---|
| Resolution date | 22 August 2025 |
| Scheduled Appointment Date | 1 October 2025 |
| Name of appointee | 堀 英紀 |
| Appointee's new position | 執行役員（株式会社あすか製薬メディカル 代表取締役 社長、あすか製薬株式会社 フェムテック事業推進室長 兼務） |
| Appointee's previous position | （株式会社あすか製薬メディカル）取締役、あすか製薬株式会社 フェムテック事業推進室長 兼務 |
| Number of directors after the change | 9 (including 4 outside directors) |
Items this document does not state (15)
Date of departureAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company has not provided any specific explanation for the changes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.